# Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

> **NCT05524857** · PHASE1 · TERMINATED · sponsor: **Joseph Jurcic** · enrollment: 2 (actual)

## Conditions studied

- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Fedratinib Oral Capsule 300 mg
- **DRUG:** Decitabine 20 mg/m2
- **DRUG:** Fedratinib Oral Capsule 400 mg

## Key facts

- **NCT ID:** NCT05524857
- **Lead sponsor:** Joseph Jurcic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-28
- **Primary completion:** 2024-04-09
- **Final completion:** 2024-04-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Closed by Sponsor
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05524857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05524857, "Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05524857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*